All In MedTech

Device Trial Radar · NCT05399537

Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT

A Safety Evaluation of Prismocitrate 18 in Patients Receiving Continuous Renal Replacement Therapy (CRRT)

Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

Jul 12, 2024

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Vantive Health LLCNot on our public-company list
Sponsor type
Industry
Collaborators
Baxter Healthcare Corporation
First posted
Jun 1, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.

Conditions

  • Regional Citrate Anticoagulation (RCA)
  • Continuous Renal Replacement Therapy (CRRT)
  • Acute Kidney Injury (AKI)

Interventions

  • Prismocitrate 18Drug

    Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.

  • PrisMax System Version 3.x with calcium line accessoryDevice

    The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with symptomatic hypocalcemia related to Prismocitrate 18 administrationTime frame: Day 1 up to Day 10

2 more outcomes with a free account

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham/UAB

    Birmingham, Alabama · Recruiting

13 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.